Global longitudinal strain is a sensitive early marker of myocardial dysfunction associated with cardiotoxic medications, potentially alerting clinicians to toxicity before reductions in ejection fraction.
Does global longitudinal strain (GLS) provide early detection of myocardial damage in patients receiving cardiotoxic medications compared to ejection fraction?
Global longitudinal strain is a sensitive imaging biomarker that can detect drug-induced cardiotoxicity earlier than traditional ejection fraction measurements.
Ejection fraction (EF) is the principal parameter used clinically to assess cardiac function and provides prognostic information. However, significant myocardial damage can be present despite preserved EF. Recently, the measurement of left ventricle (LV) deformation by global longitudinal strain (GLS) has been introduced as a novel early marker of cardiac dysfunction. Cardiotoxicity is a frequent side effect of several drugs most notably those used in the treatment of cancer. Although oncology drugs remain the best known cardiotoxic medications, many other drugs can potentially affect LV function. The early recognition of LV dysfunction due to cardiotoxicity is important and of increasing clinical relevance particularly with the rapid pace of development of new drugs. The aim of our review is to provide an overview of the current literature regarding utility of GLS to assess drug-induced myocardial damage. We propose that GLS is a sensitive early marker of myocardial dysfunction associated with the use of certain medications with high risk of cardiotoxicity. Thus, the use of this technique can potentially alert the clinician to myocardial toxicity before reductions in EF are seen.
Sartorio et al. (Thu,) conducted a review in Drug-induced myocardial damage / Cardiotoxicity. Global longitudinal strain (GLS) vs. Ejection fraction (EF) was evaluated on Early recognition of left ventricle dysfunction due to cardiotoxicity. Global longitudinal strain is a sensitive early marker of myocardial dysfunction associated with cardiotoxic medications, potentially alerting clinicians to toxicity before reductions in ejection fraction.